Complement C5a/C5a Des-Arg (Neo-epitope des-Arg) 抗体
适用: 人
Func, IA, IHC (fro), IHC (p)
宿主: 小鼠
Monoclonal
2952
unconjugated
(4 references)-
- 抗原
- Complement C5a/C5a Des-Arg
- 抗原表位
- Neo-epitope des-Arg
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- 非结合性
- 应用范围
- Functional Studies (Func), Immunoassay (IA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- 交叉反应 （详细）
- Cross reactivity: Human C5 : No
- 过滤
- 0.2 μm filtered
- 克隆位点
- 2952
- 亚型
- IgG1
-
-
- 应用备注
- For immunohistochemistry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting. Positive Human Granulocytes control
- 限制
- 仅限研究用
-
- 缓冲液
- PBS containing 0.1 % bovine serum albumin.
- 储存条件
- 4 °C
- 储存方法
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
-
-
: "Drusen complement components C3a and C5a promote choroidal neovascularization." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, Issue 7, pp. 2328-33, (2006) (PubMed).
: "Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome." in: Clinical and diagnostic laboratory immunology, Vol. 3, Issue 2, pp. 175-83, (1997) (PubMed).
: "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis." in: Immunotechnology : an international journal of immunological engineering, Vol. 2, Issue 2, pp. 115-26, (1997) (PubMed).
: "Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures." in: Journal of immunological methods, Vol. 166, Issue 1, pp. 35-44, (1993) (PubMed).
-
: "Drusen complement components C3a and C5a promote choroidal neovascularization." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, Issue 7, pp. 2328-33, (2006) (PubMed).
-
- 抗原
- Complement C5a/C5a Des-Arg
- 背景
- The monoclonal antibody 2952 recognizes a neo-epitope on human complement protein C5a/C5a des-Arg. C5 is involved in the activation of the lytic pathway within the complement system which is an important factor in innate immunity. The activation pathways lead via C3 to the cleavage of the fifth complement component C5. During complement activation, C5 is proteolytically cleaved and the anaphylatoxic peptide C5a is generated. C5a is a small polypeptide consisting of 74 amino acids (~11 kDa) and is derived from the N-terminus of the α-chain. C5a itself is very short-lived and in serum is cleaved rapidly into the more stable, though biologically still active C5a-desArg (also called acylation stimulating protein, ASP). C5a acts as a potent anaphylatoxin causing smooth muscle contraction, vasodilatation, increased vascular permeability, basophil and mast cell degranulation and lysosomal enzyme release. In addition, C5a is a potent chemotactic factor for neutrophils, eosinophils, basophils and monocytes. C5a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. Elevation of C5a is associated with increased cardiovascular risk in patients with advanced atherosclerosis. Also, C5a is closely associated with the capillary leak syndrome in leukemic children after bone marrow transplantation. C5a is also a marker in urine for predicting the onset of acute graft rejection after kidney transplantation. Monoclonal antibody 2952 is a subclone of clone 2925. Immunogen ISHKDMQLG (C5a amino acid 65-73)
-
You are here:
